News
ICViewExpert PerspectivesMedical World NewsPathogen PlaybookVideosWebinars
Conference CoverageConference ListingAPIC Chapters
Infection Control TodaySupplements And Featured Publications
CME/CEEditorial Advisory BoardJob BoardPartnersSponsoredWhitepapers
Subscribe
Educator of the Year Official Rules2024 Educator of the Year Winner2023 Educator of the Year WinnerEducator of the Year
Advanced TechnologyAdvanced TechnologyAdvanced Technology
Bug of the Month
COVID-19
Environmental ServicesEnvironmental Services
HAIs
Hand Hygiene
IC Trends
Long-Term CareLong-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Policy
PreventionPreventionPreventionPrevention
Sterile ProcessingSterile Processing
Surface Disinfection
Vascular Access
Spotlight -
  • IC Trends
  • Bug of the Month
  • Featured Articles
  • Featured Columns
  • Pathogen Playbook
Advanced TechnologyAdvanced TechnologyAdvanced Technology
Bug of the Month
COVID-19
Environmental ServicesEnvironmental Services
HAIs
Hand Hygiene
IC Trends
Long-Term CareLong-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Policy
PreventionPreventionPreventionPrevention
Sterile ProcessingSterile Processing
Surface Disinfection
Vascular Access
    • News
    • Subscribe
Advertisement

Study Links Gut-Homing Protein Levels With HIV Infection Risk, Disease Progression

February 6, 2018
Article



Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Courtesy of NIAID

For the first time, scientists have shown a relationship between the proportion of key immune cells that display high levels of a gut-homing protein called alpha-4 beta-7 at the time of HIV infection and health outcomes. Previous research illustrated this relationship in monkeys infected with a simian form of HIV.

The new study found that women who had more CD4+ T cells displaying high levels of alpha-4 beta-7 on their surface were more likely to become infected with HIV, and the virus damaged their immune systems more rapidly, than women with fewer such cells. The National Institutes of Health co-funded the study with the South African Medical Research Council as part of the U.S.–South Africa Program for Collaborative Biomedical Research. In addition, NIH scientists collaborated on the study. The report appears online today in the journal Science Translational Medicine.

“Our findings suggest that having a high frequency of alpha-4 beta-7-expressing CD4+ T cells, which HIV preferentially infects, leads to more HIV-infected CD4+ T cells moving to the gut, which in turn leads to extensive damage to gut-based immune cells,” said Anthony S. Fauci, MD. Fauci co-authored the paper as chief of the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. He also is director of NIAID.

The study was led by Lyle McKinnon, PhD, and Aida Sivro, PhD, both researchers at the Centre for the AIDS Programme of Research in South Africa (CAPRISA) in Durban, South Africa. McKinnon is also an assistant professor in the Rady Faculty of Health Sciences at the University of Manitoba in Winnipeg, Canada, and an honorary lecturer at the University of Nairobi in Kenya.

The research team compared the percentage of CD4+ T cells displaying high levels of alpha-4 beta-7 in blood samples drawn from 59 women shortly before they acquired HIV to the percentage of such cells in 106 women who remained HIV negative. Aged 18 to 40 years, the women were selected from participants in the CAPRISA 004 study (link is external), which evaluated the safety and efficacy of tenofovir gel for HIV prevention in KwaZulu-Natal, South Africa, from 2007 to 2010. Understanding HIV acquisition and disease progression among African women is especially important because women accounted for nearly 60 percent of new HIV infections among adults in sub-Saharan Africa in 2016.

The proportion of CD4+ T cells with high levels of alpha-4 beta-7 had an effect, albeit modest, on the risk of acquiring HIV among both the women in the CAPRISA 004 study and a separate cohort of 41 female sex workers in Kenya. The risk of HIV acquisition rose by 18 percent for each one percent increase in alpha-4 beta-7 protein. The authors show a similar association in monkeys that were vaginally exposed to a simian form of HIV.

The proportion of CD4+ T cells with high levels of alpha-4 beta-7 strongly affected how quickly HIV damaged the immune system. CD4+ T cell levels declined twice as fast among women with higher pre-infection levels of alpha-4 beta-7 as among women with lower pre-infection levels. In addition, the amount of HIV in the blood within a few months of infection was greater in women with higher pre-infection levels of alpha-4 beta-7 than in women with lower pre-infection levels. The mechanism for the immune system damage likely was HIV-related damage to the gut, the scientists report, as higher pre-infection levels of alpha-4 beta-7 were associated with higher levels of a biological marker of gut damage.

The scientists found that HIV targets CD4+ T cells displaying alpha-4 beta-7 very early in infection, particularly in the gut. In this regard, the researchers looked at data from the U.S. Military HIV Research Program-led RV254 clinical trial at the Thai Red Cross in Bangkok, Thailand, and found that starting antiretroviral therapy (ART) right after HIV diagnosis did not prevent the depletion of CD4+ T cells from the gut or facilitate reconstitution of the depleted cells.

“These findings suggest that interventions in addition to ART may be needed to restore CD4+ T cells in the GI tracts of people living with HIV,” said McKinnon. “One such intervention could be an anti-alpha-4 beta-7 antibody called vedolizumab, which is FDA-approved for the treatment of ulcerative colitis and Crohn’s disease.”

In previous studies led by Fauci and Aftab A. Ansari, PhD, of Emory University in Atlanta, a monkey-adapted form of vedolizumab contributed to the near-replenishment in monkeys of CD4+ T cells that had been destroyed by a simian form of HIV. Based on this and related findings, NIAID initiated an early-phase clinical trial in 2017 to determine whether short-term treatment with vedolizumab in combination with ART could generate sustained HIV remission in people living with HIV. The study is taking place at the NIH Clinical Research Center in Bethesda, Md. Preliminary results are expected later this year. More information about the study is available at ClinicalTrials.gov under study identifier NCT02788175.

Source: National Institutes of Health (NIH)

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content

Stretcher and HAIs  (Image courtesy of author through AI)

How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels

Donald Sipp, MBA, RESE, CHESP, CHTI-2, CMIP, PMP
July 3rd 2025
Article

Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.


Hot Topics With Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC

Hot Topics for IPC on July 2, 2025

Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC
July 2nd 2025
Article

This Hot Topics for IPC covers the latest on ASPR, AMR, vaccines, and a study on AMR and livestock manure from Michigan State University.


The Clean Bite

Personal Protective Equipment (PPE) for Dental Professionals: A Layered Defense

Sherrie Busby, EDDA, CDSO, CDIPC
July 1st 2025
Article

Dental infection control expert Sherrie Busby tackles PPE missteps, from chin-bra masks to cropped lab coats, reminding dental teams that proper protection is crucial, not optional.


Rebecca Battjes, MPH, CIC, FAPIC; Vidya Nankoosingh, MLT, CIC; and Peter Teska, MBA

Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25

Tori Whitacre Martonicz
June 30th 2025
Article

Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.


ACIP decides on vaccinations   (Adobe Stock 606491608 by N Lawrenson/peopleimages.com)

New ACIP Panel Backs Seasonal Flu, RSV Vaccinations, but Divisions Emerge Over Thimerosal and Infant Dosing

Richard Payerchin
June 27th 2025
Article

In its first major session under newly appointed leadership, the revamped Advisory Committee on Immunization Practices (ACIP) voted to support flu and RSV vaccinations for the 2025–2026 season, but internal debate over vaccine preservatives, access equity, and risk assessment highlighted the ideological and scientific tensions now shaping federal vaccine policy.


US Department of Health and Human Services

A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides

Richard Payerchin
June 26th 2025
Article

As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.

Related Content

Stretcher and HAIs  (Image courtesy of author through AI)

How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels

Donald Sipp, MBA, RESE, CHESP, CHTI-2, CMIP, PMP
July 3rd 2025
Article

Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.


Hot Topics With Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC

Hot Topics for IPC on July 2, 2025

Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC
July 2nd 2025
Article

This Hot Topics for IPC covers the latest on ASPR, AMR, vaccines, and a study on AMR and livestock manure from Michigan State University.


The Clean Bite

Personal Protective Equipment (PPE) for Dental Professionals: A Layered Defense

Sherrie Busby, EDDA, CDSO, CDIPC
July 1st 2025
Article

Dental infection control expert Sherrie Busby tackles PPE missteps, from chin-bra masks to cropped lab coats, reminding dental teams that proper protection is crucial, not optional.


Rebecca Battjes, MPH, CIC, FAPIC; Vidya Nankoosingh, MLT, CIC; and Peter Teska, MBA

Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25

Tori Whitacre Martonicz
June 30th 2025
Article

Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.


ACIP decides on vaccinations   (Adobe Stock 606491608 by N Lawrenson/peopleimages.com)

New ACIP Panel Backs Seasonal Flu, RSV Vaccinations, but Divisions Emerge Over Thimerosal and Infant Dosing

Richard Payerchin
June 27th 2025
Article

In its first major session under newly appointed leadership, the revamped Advisory Committee on Immunization Practices (ACIP) voted to support flu and RSV vaccinations for the 2025–2026 season, but internal debate over vaccine preservatives, access equity, and risk assessment highlighted the ideological and scientific tensions now shaping federal vaccine policy.


US Department of Health and Human Services

A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides

Richard Payerchin
June 26th 2025
Article

As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.

Advertise
About Us
Editorial Board
Contact Us
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News